Current treatment options of choroidal melanoma include enucleation ... and the advent of gene-expression profiling analysis (BRAF, GNAQ mutations) led to classification of uveal melanomas ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

Some residual BRAF signaling in tumor cells persists ... have ended the futility and nihilism that have long dominated melanoma treatment. It will take time to sort out the best combinations ...

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

which has previously won regulatory approvals for the combination as treatment for BRAF-mutated melanoma, non-small cell lung cancer (NSCLC) and thyroid cancers. Use of Tafinlar/Mekinist in ...

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for ...